|Articles|July 13, 1994

CIS Bio to license tracer technology

French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new

French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new technetium-labeled compounds. The agreementincludes rights for a nuclear cardiology agent that shows promisein imaging myocardial ischemia and infarction, according to thecompany.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Latest CME